Multiple Myeloma Poster Presentations

ABSTRACTPOMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE-BASED TREATMENT FAILURE

Author(s): David S. Siegel, et al. ABSTRACT

Conclusion
These results indicate that POM + LoDEX + DARA is an effective and tolerable regimen when sequenced in earlier lines of therapy in patients with RRMM and in whom first- or second-line therapy with a LEN-based treatment failed.

 

POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN CASE OF SUBOPTIMAL RESPONSE TO POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: RESULTS OF THE GMMG-PERSPECTIVE TRIAL Author(s): Katja Weisel, et al. ABSTRACT

Conclusion
In RRMM patients, addition of CY to standard POM + Dex treatment is able to overcome lack of response or primary resistance to POM + Dex in a marked proportion of patients. PFS, TTNT and OS of the IIT compares favorably with published data for POM + Dex alone. With a favorable toxicity profile of the triple combination, primary addition of CY to POM + Dex should be considered in future to further optimize efficacy and durability of responses in POM + Dex standard treatment.

 

SAFETY AND EFFICACY OF POMALIDOMIDE + LOW-DOSE DEXAMETHASONE IMMEDIATELY FOLLOWING LENALIDOMIDE-BASED TREATMENT FAILURE IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

Author(s): David S. Siegel, et al. ABSTRACT

Conclusion
POM + LoDEX is a safe and effective third-line Tx for pts with RRMM following second-line failure of LEN-based Tx, including pts with prior exposure to PI or BORT. All pts, including those with prior PI or BORT Tx, experienced lower rates of hematologic AEs and longer median PFS than what has been previously reported for other studies using POM + LoDEX in later lines of Tx.

 

SELINEXOR COMBINED WITH POMALIDOMIDE AND LOW DOSE DEXAMETHASONE (SPD) IN A RELAPSED / REFRACTORY MULTIPLE MYELOMA PATIENT POPULATION

Author(s): Christine Chen, et al. ABSTRACT

Conclusion
Enrollment is ongoing to evaluating once weekly selinexor in combination with Pd. This all oral combination of selinexor, pom and dex (SPd) has significant clinical activity with an ORR 63% in pom naive pts with heavily pretreated MM compared to previously published data of 30% ORR. No unexpected adverse events were noted. Phase 1 dose escalation of the combination of SPd is ongoing to define the RP2D. SPd appears active and supports further clinical development in RRMM.